Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton Sells 83,660 Shares

Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton sold 83,660 shares of the business’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the transaction, the chief executive officer now directly owns 701,947 shares in the company, valued at approximately $645,791.24. The trade was a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Biodesix Stock Down 1.1 %

Shares of NASDAQ BDSX traded down $0.01 during trading on Wednesday, reaching $0.94. 170,859 shares of the stock were exchanged, compared to its average volume of 460,809. The company has a market capitalization of $136.74 million, a price-to-earnings ratio of -2.41 and a beta of 1.06. The business’s 50-day moving average price is $1.26 and its 200 day moving average price is $1.49. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. Biodesix, Inc. has a twelve month low of $0.86 and a twelve month high of $2.04.

Institutional Trading of Biodesix

Several institutional investors have recently added to or reduced their stakes in BDSX. Perkins Capital Management Inc. raised its holdings in Biodesix by 74.7% in the third quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock valued at $1,290,000 after acquiring an additional 310,000 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in Biodesix in the third quarter valued at $262,000. Barclays PLC raised its holdings in Biodesix by 1,140.5% in the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after acquiring an additional 21,179 shares in the last quarter. Geode Capital Management LLC increased its stake in Biodesix by 50.7% during the third quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock valued at $1,433,000 after purchasing an additional 270,724 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in Biodesix during the third quarter valued at $10,849,000. 20.96% of the stock is owned by institutional investors and hedge funds.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.